White matter disease in cerebral organic acid disorders: Clinical implications and suggested pathomechanisms

Neuropediatrics

Volumn 33, Issue 5, 2002, Pages 225-231

  Kolker S ^a   Mayatepek, E ^a   Hoffmann, G F ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Excitotoxicity; Glutamate Receptors; Leukencephalopathy; Myelination; Organic Acid Disorders; Reactive Oxygen Species

Indexed keywords

2 HYDROXYGLUTARIC ACID; 4 AMINOBUTYRIC ACID; ASPARTOACYLASE; CARBOXYLIC ACID; DEXTRO 2 HYDROXYGLUTARIC ACID; GLUTAMATE RECEPTOR; GLUTARIC ACID; GLUTARYL COENZYME A DEHYDROGENASE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

2 HYDROXYGLUTARIC ACIDURIA; ACIDOSIS; ACIDURIA; ASPARTOACYLASE DEFICIENCY; BRAIN DISEASE; CEREBRAL ORGANIC ACID DISEASE; CLINICAL FEATURE; CYTOTOXICITY; DEMYELINATING DISEASE; ENERGY METABOLISM; ENZYME DEFECT; GABAERGIC TRANSMISSION; GLUTARYL COENZYME A DEHYDROGENASE DEFICIENCY; HUMAN; HYPERAMMONEMIA; HYPOGLYCEMIA; LEUKOENCEPHALOPATHY; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; STRUCTURE ANALYSIS; WHITE MATTER; WHITE MATTER DISEASE;

BRAIN DISEASES, METABOLIC; CEREBRAL CORTEX; CHILD; DEMYELINATING DISEASES; FEMALE; HUMANS; INFANT; MAGNETIC RESONANCE IMAGING; MALE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0036823408     PISSN: 0174304X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-36741     Document Type: Review

References (66)

1. Adachi M, Aronson SM. Studies on spongy degeneration of the central nervous system (van Bogaert-Bertrand type). In: Aronson SM, Volk BW (Eds). Inborn Disorders of Sphingolipid Metabolism. Oxford: Pergamon Press, 1967: 129
2. Albin RL, Greenamyre JT. Alternative excitotoxic hypothesis. Neurology 1992; 42: 733-738
3. Back SA, Gan X, Li Y, Rosenberg PA, Volpe JJ. Maturation-dependent vulnerability of oligodendrocytes to oxidative stress-induced death caused by glutathione depletion. J Neurosci 1998; 18: 6241-6253
4. Barres BA, Raff MC, Gaese F, Bartke I, Dechant G, Barde YA. A crucial role for neurotrophin-3 in oligodendrocyte development. Nature 1994; 367: 371-375
5. Barth PG, Hoffmann GF, Jaeken J, Wanders RJA, Duran M, Jansen GA et al. L-2-Hydroxyglutaric acidaemia: clinical and biochemical findings in 12 patients and preliminary report on L-2-hydroxyacid dehydrogenase. J Inherit Metab Dis 1993; 16: 753-761
6. Beal MF, Brouillet E, Jenkins BG, Ferrante RJ, Kowall NW, Miller JM et al. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 1993; 13: 4181-4192
7. Beaudet AL. Aspartoacylase deficiency (Canavan disease). In: Scriver CR, Beaudet AL, Valle AD, Sly WS (Eds). The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill, 2001: 5799-5805
8. Brismar J, Brismar G, Gascon G, Ozand P. Canavan disease: CT and MR imaging of the brain. Am J Neuroradiol 1990; 11: 805-810
9. Brismar J, Ozand PT. CT and MR of the brain in glutaric acidemia type I: a review of 59 published cases and a report of 5 new patients. Am J Neuroradiol 1995; 16: 675-683
10. Burlina AP, Ferrari V, Divry P, Gradowska W, Jakobs C, Bennett MJ et al. N-Acetylaspartylglutamate in Canavan disease: an adverse effector? Eur J Pediatr 1999; 158: 406-409
11. Chew LJ, Fleck MW, Wright P, Scherer SE, Mayer ML, Gallo V. Growth factor-induced transcription of GluR1 increases functional AMPA receptor density in glial progenitor cells. J Neurosci 1997; 17: 227-240
12. Chow CW, Haan EA, Goodman SI, Anderson RM, Evans WA, Kleinschmidt-DeMasters BK et al. Neuropathology of glutaryl-CoA dehydrogenase deficiency. Acta Neuropathol 76: 590-594
13. Da Silva CG, Ribeiro CAJ, Leipnitz G, Dutra-Filho CS, Wyse ATS, Wannmacher CMD et al. Inhibition of cytochrome c oxidase activity in rat cerebral cortex and human skeletal muscle by D-2-hydroxyglutaric acid in vitro. Biochim Biophys Acta 2002; 1586: 81-91
14. De Mello CF, Kölker S, Ahlemeyer B, de Souza FR, Fighera MR, Mayatepek E et al. Intrastriatal administration of 3-hydroxyglutaric acid induces convulsions and excitotoxic lesions in rats. Brain Res 2001; 916: 70-75
15. D'Incerti L, Farina L, Moroni I, Uziel G, Savoiardi M. L-2-Hydroxyglutaric aciduria: MRI in seven cases. Neuroradiology 1998; 40: 727-733
16. Dugan LL, Sensi SL, Canzoniero LM, Handran SD, Rothman SM, Lin TS et al. Mitochondrial production of reactive oxygen species in cortical neurons following exposure to N-methyl-D-aspartate. J Neurosci 1995; 15: 6377-6388
17. Follett PL, Rosenberg PA, Volpe JJ, Jensen FE. NBQX attenuates excitotoxic injury in developing white matter. J Neurosci 2000; 20: 9235-9241
18. Gallo V, Wright PW, McKinnon RD. Expression and regulation of a glutamate receptor subunit by bFGF in oligodendrocyte progenitors. Glia 1994; 10: 149-153
19. Gegelashvili G, Schousboe A. High affinity glutamate transporters: regulation of expression and activity. Mol Pharmacol 1997; 52: 5-15
20. Greene JG, Porter RHP, Eller RV, Greenamyre JT. Inhibition of succinate dehydrogenase by malonic acid produces an excitotoxic lesion in rat striatum. J Neurochem 1993; 61: 1151-1154
21. Hanefeld F, Kruse B, Bruhn H, Frahm J. In vivo proton magnetic resonance spectroscopy of the brain in a patient with L-2-hydroxyglutaric aciduria. Pediatr Res 1994; 35: 614-616
22. Hardy R, Reynolds RJ. Neuron-oligodendroglial interactions during central nervous system development. Neurosci Res 1993; 36: 121-126
23. Heyes MP. Hypothesis: a role for quinolinic acid in the neuropathology of glutaric aciduria type 1. Can J Neurol Sci 1987; 14: 441-443
24. Hoffmann GF, Trefz FK, Barth P, Böhles JH, Biggemann B, Bremer HJ et al. Glutaryl-CoA deficiency: a distinct encephalopathy. Pediatrics 1991; 88: 1194-1203
25. Hoffmann GF, Gibson KM, Trefz FK, Nyhan WL, Bremer HJ, Rating D. Neurological manifestations of organic acid disorders. Eur J Ped 1994; 153 (Suppl 1): S94-100
26. Hoffmann GF, Athanassopoulos S, Burlina AB, Duran M, deKlerck JBC, Lehnert W et al. Clinical course, early diagnosis, treatment, and prevention of disease in glutaryl-CoA dehydrogenase deficiency. Neuropediatrics 1996; 27: 115-123
27. Jacobson M. Developmental Neurobiology, 3rd ed. New York: Plenum Press, 1991: 776
28. Kagawa T, Wada T, Ikenaka K. Regulation of oligodendrocyte development. Microsc Res Tech 2001; 52: 740-745
29. Kavanaugh B, Beesley J, Itoh T, Itoh A, Grinspan J, Pleasure D. Neurotrophin-3 (NT-3) diminishes susceptibility of the oligodendroglial lineage to AMPA glutamate receptor-mediated excitotoxicity. J Neurosci Res 2000; 60: 725-732
30. Koeller DM, Woontner M, Crnic LS, Kleinschmidt-DeMasters B, Stephens J, Hunt EL, Goodmann SI. Biochemical, pathological and behavioral analysis of a mouse model of glutaric aciduria type 1. Hum Mol Gen 2002; 11: 347-357
31. Kölker S, Ahlemeyer B, Krieglstein J, Hoffmann GF. Maturation-dependent neurotoxicity of 3-hydroxyglutaric and glutaric acids in vitro: A new pathophysiological approach to glutaryl-CoA dehydrogenase deficiency. Pediatr Res 2000; 47: 495-503
32. Kölker S, Ahlemeyer B, Hühne R, Krieglstein J, Hoffmann GF. Potentiation of 3-hydroxyglutarate neurotoxicity following induction of astrocytic iNOS in neonatal rat hippocampal cultures. Eur J Neurosci 2001; 13: 2115-2122
33. Kölker S, Ahlemeyer B, Krieglstein J, Hoffmann GF. Contribution of reactive oxygen species to 3-hydroxyglutarate neurotoxicity in primary neuronal cultures from chick embryo telencephalons. Pediatr Res 2001; 50: 76-82
34. Kölker S, Okun JG, Hörster F, Ahlemeyer B, Krieglstein J, Mayatepek E, Hoffmann GF. L-2-Hydroxyglutarazidurie: Evaluation exzitotoxischer Pathomechanismen. In: Aksu F (ed). Aktuelle Neuropädiatrie 2001. Nürnberg: Novartis-Pharma Verlag, 2002: 258-261
35. Kölker S, Okun JG, Ahlemeyer B, Wyse AT, Hörster F, Kohlmüller D et al. Chronic treatment with glutaric acid induces partial tolerance to excitotoxicity in neuronal cultures from chick embryo telencephalon. J Neurosci Res 2002; 68: 424-432
36. Kölker S, Pawlak V, Ahlemeyer B, Okun JG, Hörster F, Mayatepek E et al. NMDA receptor activation and respiratory chain complex V inhibition contribute to neurodegeneration in D-2-hydroxyglutaric aciduria. Eur J Neurosci 2002; 16: 21-28
37. Kramer EM, Schardt A, Nave KA. Membrane traffic in myelinating oligodendrocytes. Microsc Res Tech 2001; 52: 656-671
38. Levine SM, Goldman JE. Spatial and temporal patterns of oligodendrocyte differentiation in rat cerebrum and cerebellum. J Comp Neurol 1988; 277: 441-455
39. Li C, Tropak, Gerlai R, Clapoff S, Abramow-Newerly W, Trapp B et al. Myelination in the absence of myelin-associated glycoprotein. Nature 1994; 369: 747-750
40. Lima TTF, Begnini J, de Bastiani J, Fialho DB, Jurach A, Pereira Ribeiro MC et al. Pharmacological evidence for GABAergic and glutamatergic involvement in the convulsant and behavioral effects of glutaric acids. Brain Res 1998; 802: 55-60
41. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. New Engl J Med 1994; 330: 613-622
42. Lucas DR, Newhouse JP. The toxic effect of sodium L-glutamate on the inner layers on the retina. Arch Ophthalmol 1957; 58: 193-201
43. Matalon R, Michals K, Sebesta D, Deanching M, Gashkoff P, Casanova J. Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease. Am J Med Genet 1988; 29: 463-471
44. Matalon R, Michals K, Kaul R. Canavan disease: from spongy degeneration to molecular analysis. J Pediatr 1995; 127: 511-517
45. Matalon R, Rady PL, Platt KA, Skinner HB, Quast MJ, Campbell GA et al. Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system. J Gene Med 2000; 2: 165-175
46. Matute C, Sanchez-Gomez MV, Martinez-Millan L, Miledi R. Glutamate-mediated toxicity in optic nerve oligodendrocytes. Proc Natl Acad Sci 1997; 94: 8830-8835
47. McDonald JW, Althomsons SP, Hyrc KL, Choi DW, Goldberg MP. Oligodendrocytes from forebrain are highly vulnerable to AMPA/kainate receptor-mediated excitotoxicity. Nat Med 1998; 4: 291-297
48. McKinnon RD, Matsui T, Dubois-Dalq M, Aaronson SA. FGF modulates the PDGF-driven pathway of oligodendrocyte development. Neuron 1990; 5: 603-614
49. Morell P, Quarles RH, Norton WT. Myelin formation, structure, and biochemistry. In: Siegel GF (Ed). Basic Neurochemistry: Molecular, Cellular, and Medical Aspects. 5th ed. New York: Raven Press, 1994: 117-143
50. Muntau AC, Röschinger W, Merkenschlager A, van der Knaap MS, Jakobs C, Duran M et al. Combined D-2-and L-2-hydroxyglutaric aciduria with neonatal onset encephalopathy: a third biochemical variant of 2-hydroxyglutaric aciduria? Neuropediatrics 2000; 31: 137-140
51. Neale JH, Bzdega T, Wroblewska B. N-Acetylaspartylglutamate: the most abundant peptide neurotransmitter in the mammalian central nervous system. J Neurochem 2000; 75: 443-452
52. Nyhan WL, Shelton D, Jakobs C, Holmes B, Bowe C, Curry CJR et al. D-2-hydroxyglutaric aciduria. J Child Neurol 1995; 10: 137-142
53. Olney JW. Brain lesion, obesity and other disturbances in mice treated with monsodium glutamate. Science 1969; 164: 719-721
54. Passani L, Elkabes S, Coyle JT. Evidence for the presence of N-acetylas-partylglutamate in cultured oligodendrocytes and LPS activated microglia. Brain Res 1998; 25: 143-145
55. Patneau DK, Wright PW, Winters C, Mayer ML, Gallo V. Glial cells of the oligodendrocyte lineage express both kainate-and AMPA-preferring subtypes of glutamate receptor. Neuron 1994; 12: 357-371
56. Pende M, Holtzclaw LA, Curtis JL, Russell JT, Gallo V. Glutamate regulates intracellular calcium and gene expression in oligodendrocyte progenitors through the activation of DL-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. Proc Natl Acad Sci 1994; 91: 3215-3219
57. Pliss L, Fitz-Gibbon T, Balcar VJ, Stasny F. Neurotoxicity of NAAG in vivo is sensitive to NMDA antagonists and mGluR II ligands. Neuroreport 2000; 11: 3651-3654
58. Puchalski RB, Louis JC, Brose N, Traynelis SF, Egebjerg J, Kukekov V et al. Selective RNA editing and subunit assembly of native glutamate receptors. Neuron 1994; 13: 131-146
59. Quarles RH. Glycoproteins of myelin sheats. J Mol Neurosci 1997; 8: 1-12
60. Raff MC, Lillien LE, Richardson WD, Burne JF, Noble MD. Platelet-derived growth factor from astrocytes drives the clock that times oligodendrocyte development in culture. Nature 1988; 303: 390-396
61. Toft PB, Geiß-Holtorff R, Rolland MO, Pryds O, Müller-Forell W, Christensen E et al. Magnetic resonance imaging in juvenile Canavan disease. Eur J Pediatr 1993; 152: 750-753
62. Ullrich K, Flott-Rahmel B, Schluff P, Musshoff U, Das A, Lücke T et al. Glutaric aciduria type I: Pathomechanism of neurodegeneration. J Inherit Metab Dis 1999; 22: 392-403
63. Valivullah HM, Lancaster J, Sweetman PM, Neale JH. Interactions between N-acetylaspartylglutamate and AMPA, kainate, and NMDA binding sites. J Neurochem 1994; 63: 1714-1719
64. Van der Knaap MS, Valk J. Magnetic Resonance of Myelin, Myelination, and Myelin Disorders. 2nd ed. Berlin, Heidelberg, New York: Springer, 1995
65. Van der Knaap MS, Jakobs C, Hoffmann GF, Nyhan WL, Renier WO, Smeitink JAM et al. D-2-hydroxyglutaric aciduria: biochemical marker or clinical disease entity? Ann Neurol 1999; 45: 111-119
66. Yonezawa M, Back SA, Gan X, Rosenberg PA, Volpe JJ. Cystine deprivation induces oligodendroglial death: rescue by free radical scavengers and by a diffusible glial factor. J Neurochem 1996; 67: 566-573